--- title: "AbbVie prices four series of senior notes" url: "https://aibio.space/news/abbvie-prices-four-series-senior-notes-expects-about-3-98-billion-net/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-02-19" section: "Financings" tickers: "NYSE:ABBV" source: "https://www.sec.gov/Archives/edgar/data/1551152/000110465925015015/tm255723d4_8k.htm" summary: "The notes mature in 2028, 2030, 2035 and 2055. AbbVie plans to use the money and cash on hand to repay 2025 senior notes, and the sale is expected to close" --- By the aibio.space news desk. Sources - [AbbVie Inc. Form 8-K filed February 19, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1551152/000110465925015015/tm255723d4_8k.htm) - [AbbVie Inc. exhibit tm255723d4_ex1-1.htm to the February 19, 2025 Form 8-K (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1551152/000110465925015015/tm255723d4_ex1-1.htm) - [AbbVie Inc. Form 10-K filed February 14, 2025: business overview and signatures (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm) [ABBV](https://aibio.space/companies/abbvie/) 2025-02-19 # AbbVie prices four series of senior notes, expects about $3.98 billion in net proceeds Tickers [ABBV](https://aibio.space/companies/abbvie/) The notes mature in 2028, 2030, 2035 and 2055. AbbVie plans to use the money and cash on hand to repay 2025 senior notes, and the sale is expected to close February 26, 2025. ## Key facts - **Company**: AbbVie Inc. (NYSE: ABBV) - **News type**: Financings - **Primary source**: [AbbVie Inc. Form 8-K filed February 19, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1551152/000110465925015015/tm255723d4_8k.htm) *A city skyline in morning haze. CC0, via rawpixel. The picture shows the field, not the companies named.* AbbVie Inc. (NYSE: [ABBV](https://aibio.space/companies/abbvie/)) agreed on February 18, 2025 to sell four series of senior notes in a public offering and expects net proceeds of approximately $3.98 billion. The drugmaker disclosed the debt offering in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1551152/000110465925015015/tm255723d4_8k.htm) filed February 19, 2025. It plans to use the money, along with cash on hand, to repay senior notes that come due in 2025. The sale is expected to close on February 26, 2025, subject to customary closing conditions. ## The notes Under an [underwriting agreement](https://www.sec.gov/Archives/edgar/data/1551152/000110465925015015/tm255723d4_ex1-1.htm) dated February 18, 2025, AbbVie agreed to issue and sell $1,250,000,000 in aggregate principal amount of 4.650% senior notes due 2028, priced to the public at 99.867% of principal amount. It also agreed to sell $1,000,000,000 of 4.875% senior notes due 2030, priced at 99.908%, and $1,000,000,000 of 5.200% senior notes due 2035, priced at 99.857%. The fourth series is $750,000,000 of 5.600% senior notes due 2055, priced at 99.750%. The price to the public is stated as a percentage of the principal amount. The $3.98 billion estimate is after the underwriting discounts and before estimated offering expenses. ## Who is involved BofA Securities, Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Barclays Capital Inc. and Mizuho Securities USA LLC are the representatives of the several underwriters named in Schedule II of the agreement. The notes will be issued under an indenture dated as of November 8, 2012 between AbbVie and U.S. Bank Trust Company, National Association, as trustee, supplemented by Supplemental Indenture No. 11, to be dated as of February 26, 2025. The offering is registered under the Securities Act of 1933 on AbbVie's Form S-3ASR registration statement (File No. 333-284980) dated February 14, 2025. A preliminary prospectus supplement was filed on February 18, 2025, and the final prospectus supplement is to be filed on or before February 20, 2025. The 8-K says some of the underwriters or their affiliates have performed, and may again perform, investment banking, financial advisory, lending or commercial banking services for AbbVie and its subsidiaries, for which they have received customary compensation. ## What AbbVie plans to do with the money AbbVie intends to use the net proceeds, together with cash on hand, to repurchase, redeem, satisfy and discharge, defease, make a tender offer for or otherwise repay at maturity three groups of notes, and to pay any premium and accrued and unpaid interest. It may also use the money for general corporate purposes. The first group is its 3.600% senior notes due 2025, with a stated maturity date of May 14, 2025 and an outstanding principal amount of $3.750 billion. The second is its 3.800% senior notes due 2025, with a stated maturity date of March 15, 2025 and $2.890 billion outstanding. The third is the 3.800% senior notes due 2025 of Allergan Funding SCS (formerly known as Actavis Funding SCS), maturing March 15, 2025, with $130.225 million outstanding. ## Agreement terms and the company The underwriting agreement contains customary representations, warranties and covenants by AbbVie, along with customary indemnification and contribution provisions between AbbVie and the underwriters. AbbVie describes itself in its [annual report on Form 10-K](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm), filed February 14, 2025, as a global, diversified research-based biopharmaceutical company with products across immunology, oncology, aesthetics, neuroscience and eye care. The company was incorporated in Delaware on April 10, 2012 and became an independent, publicly traded company on January 1, 2013, after Abbott Laboratories distributed AbbVie's common stock to Abbott's shareholders. Scott T. Reents, Executive Vice President, Chief Financial Officer, signed the 8-K. Robert A. Michael signed the 10-K as Chief Executive Officer and Director, and Richard A. Gonzalez is listed there as Executive Chairman of the Board and Retired Chief Executive Officer. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ABBV AbbVie Inc. NYSE ยท United States Open the desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/abbvie-prices-four-series-senior-notes-expects-about-3-98-billion-net/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "AbbVie prices four series of senior notes", 2025-02-19, https://aibio.space/news/abbvie-prices-four-series-senior-notes-expects-about-3-98-billion-net/